Analysis of pathogenic role of soluble immune semaphorin in autoimmune diseases.

Analysis of pathogenic role of soluble immune semaphorin in autoimmune diseases. - Semaphorin in autoimmune diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013076

Enrollment

100

Registered

2014-02-10

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune diseases (including rheumatoid arthritis and osteoarticular diseases (including osteoarthritis and osteoporosis)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Males and females diagnosed autoimmune and osteoarticular diseases including rheumatoid arthritis, osteoarthritis, osteporosis) must -be more than 20 years old -be informed and will give written informed consent

Exclusion criteria

Exclusion criteria: -complicated with active infectious diseases -The patients who the doctors in charge consider should not enter this study.

Design outcomes

Primary

Measure	Time frame
-disease activity scores (DAS28, -CDAI/SDAI, CRP, MMP3 in RA) -Semahorins (Sema3A, Sema4A, Sema4D) -bone turnover markers -cytokines and proteases	—

Secondary

Measure	Time frame
To evaluate efficacy of conventional and biologics treatment	—

Countries

Japan

Contacts

Public ContactAtsushi Ogata

Osaka University Graduate School of Medicine Department of Respiratory Medicine, Allergy and Rheumatic DIseases

ogata@imed3.med.osaka-u.ac.jp06-6879-3833

Outcome results